CY1124970T1 - Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου - Google Patents
Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικουInfo
- Publication number
- CY1124970T1 CY1124970T1 CY20211101138T CY211101138T CY1124970T1 CY 1124970 T1 CY1124970 T1 CY 1124970T1 CY 20211101138 T CY20211101138 T CY 20211101138T CY 211101138 T CY211101138 T CY 211101138T CY 1124970 T1 CY1124970 T1 CY 1124970T1
- Authority
- CY
- Cyprus
- Prior art keywords
- preparation
- inflammation
- diseases
- treatment
- pyrazole ring
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Η παρούσα εφεύρεση σχετίζεται με παράγωγα συγχωνευμένων δακτυλίων πυραζολίου, τις μεθόδους παρασκευής τους, και χρήση αυτών στην ιατρική. Πιο συγκεκριμένα, η παρούσα εφεύρεση σχετίζεται με ένα νέο παράγωγο το οποίο αναπαρίσταται από τον τύπο (Ι), και ένα φαρμακευτικώς αποδεκτό άλας αυτού ή μια φαρμακευτική σύνθεση η οποία το περιλαμβάνει και μια μέθοδο για παρασκευή αυτού. Η παρούσα εφεύρεση σχετίζεται επίσης με χρήση των παραγώγων και του φαρμακευτικώς αποδεκτού άλατος αυτών ή της φαρμακευτικής σύνθεσης η οποία τα περιλαμβάνει στην παρασκευή θεραπευτικών παραγόντων, πιο συγκεκριμένα αναστολέων κινάσης τυροσίνης του Bruton, και παρασκευή ενός φαρμάκου για αντιμετώπιση και/ή πρόληψη όγκων και νόσων οι οποίες συνδέονται με φλεγμονή. Οι υποκαταστάτες στον τύπο (Ι) ορίζονται με τον ίδιο τρόπο όπως στην περιγραφή.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610066886.9A CN107021963A (zh) | 2016-01-29 | 2016-01-29 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症、炎症和免疫性疾病上的应用 |
| PCT/CN2016/112625 WO2017128917A1 (zh) | 2016-01-29 | 2016-12-28 | 吡唑稠环类衍生物、其制备方法及其在治疗癌症，炎症和免疫性疾病上的应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1124970T1 true CY1124970T1 (el) | 2023-01-05 |
Family
ID=59397319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20211101138T CY1124970T1 (el) | 2016-01-29 | 2021-12-30 | Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US10336755B2 (el) |
| EP (1) | EP3409672B1 (el) |
| JP (1) | JP7043409B2 (el) |
| KR (1) | KR20180104132A (el) |
| CN (2) | CN107021963A (el) |
| AU (1) | AU2016389434B2 (el) |
| CA (1) | CA3012882A1 (el) |
| CY (1) | CY1124970T1 (el) |
| DK (1) | DK3409672T3 (el) |
| ES (1) | ES2902128T3 (el) |
| HK (1) | HK1256798A1 (el) |
| HR (1) | HRP20212020T1 (el) |
| HU (1) | HUE057319T2 (el) |
| LT (1) | LT3409672T (el) |
| PL (1) | PL3409672T3 (el) |
| PT (1) | PT3409672T (el) |
| RS (1) | RS62768B1 (el) |
| SG (1) | SG11201806438UA (el) |
| SI (1) | SI3409672T1 (el) |
| WO (1) | WO2017128917A1 (el) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6922085B2 (ja) * | 2017-09-28 | 2021-08-18 | シャンハイ ハイヤン ファーマシューティカル テクノロジー カンパニー リミテッドＳｈａｎｇｈａｉ Ｈａｉｙａｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． | ４，６，７−三置換 １，２−ジヒドロピロロ［３，４−ｃ］ピリジン／ピリミジン−３−オン誘導体及びその使用 |
| WO2020151707A1 (zh) * | 2019-01-22 | 2020-07-30 | 江苏恒瑞医药股份有限公司 | 一种新型的小分子cd73抑制剂、其制备方法及其在医药上的应用 |
| WO2020187267A1 (zh) * | 2019-03-18 | 2020-09-24 | 上海海雁医药科技有限公司 | Btk抑制剂及其药学上可接受的盐和多晶型物及其应用 |
| US20220143049A1 (en) | 2019-03-21 | 2022-05-12 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3131856A1 (en) * | 2019-04-11 | 2020-10-15 | Janssen Pharmaceutica N.V. | Pyridine rings containing derivatives as malt1 inhibitors |
| JP2023500906A (ja) | 2019-11-08 | 2023-01-11 | インサーム（インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル） | キナーゼ阻害剤に対する獲得抵抗性を有するがんの処置方法 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021296163A1 (en) * | 2020-06-22 | 2023-02-02 | Corcept Therapeutics Incorporated | Quaternary indazole glucocorticoid receptor antagonists |
| WO2022048551A1 (zh) * | 2020-09-01 | 2022-03-10 | 上海海雁医药科技有限公司 | 布鲁顿酪氨酸激酶抑制剂的多晶型物及其制备方法和应用 |
| US20230192666A1 (en) * | 2021-12-21 | 2023-06-22 | Corcept Therapeutics Incorporated | Piperazine indazole glucocorticoid receptor antagonists |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0100624D0 (en) * | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds VII |
| KR20070118068A (ko) * | 2004-11-23 | 2007-12-13 | 레디 유에스 테라퓨틱스 인코포레이티드 | 신규의 이원 헤테로고리 화합물, 그 제조방법 및 이들을포함하는 조성물 |
| US20090234117A1 (en) * | 2005-05-27 | 2009-09-17 | Toshihiko Kashiwagi | Pyrazolopyrimidine Derivative |
| BRPI0621027A2 (pt) | 2006-01-13 | 2011-11-29 | Pharmacyclics Inc | composto, composição farmacêutica |
| JP5255559B2 (ja) * | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| US8338439B2 (en) | 2008-06-27 | 2012-12-25 | Celgene Avilomics Research, Inc. | 2,4-disubstituted pyrimidines useful as kinase inhibitors |
| JP5656976B2 (ja) | 2009-04-29 | 2015-01-21 | ローカス ファーマシューティカルズ インコーポレイテッド | ピロロトリアジン化合物 |
| EP2789615B1 (en) | 2009-08-11 | 2017-05-03 | Bristol-Myers Squibb Company | Azaindazoles as Btk kinase modulators and use thereof |
| JP5572715B2 (ja) * | 2009-11-12 | 2014-08-13 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ｎ−７置換プリン及びピラゾロピリミジン化合物、組成物及び使用方法 |
| CN103889962B (zh) | 2011-04-01 | 2017-05-03 | 犹他大学研究基金会 | 作为受体酪氨酸激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
| HUE033019T2 (en) | 2011-05-17 | 2017-11-28 | Principia Biopharma Inc | Tyrosine kinase inhibitors |
| EP2734523A1 (en) | 2011-07-19 | 2014-05-28 | Merck Sharp & Dohme B.V. | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides btk-inhibitors |
| CN103073508B (zh) | 2011-10-25 | 2016-06-01 | 北京大学深圳研究生院 | 激酶抑制剂及治疗相关疾病的方法 |
| HUE031094T2 (en) | 2011-11-29 | 2017-07-28 | Ono Pharmaceutical Co | Purinone derivative hydrochloride |
| JP5985658B2 (ja) | 2012-01-31 | 2016-09-06 | ナンジン アルゲン ファルマ カンパニー リミテッドＮａｎｊｉｎｇ Ａｌｌｇｅｎ Ｐｈａｒｍａ Ｃｏ． Ｌｔｄ． | ブルトンチロシンキナーゼ阻害薬としての環状分子 |
| KR20130091464A (ko) | 2012-02-08 | 2013-08-19 | 한미약품 주식회사 | 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체 |
| ES2625944T3 (es) | 2012-11-02 | 2017-07-21 | Pfizer Inc. | Inhibidores de tirosina cinasa de Bruton |
| WO2014125410A1 (en) | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
| CN103113375B (zh) | 2013-02-21 | 2017-09-15 | 南京勇山生物科技有限公司 | 一类吡唑并[3,4‑d]嘧啶类化合物及其制备方法 |
| US9242969B2 (en) * | 2013-03-14 | 2016-01-26 | Novartis Ag | Biaryl amide compounds as kinase inhibitors |
| CA2902686C (en) | 2013-04-25 | 2017-01-24 | Beigene, Ltd. | Fused heterocyclic compounds as protein kinase inhibitors |
| CA2915622C (en) | 2013-06-21 | 2020-08-18 | Zenith Epigenetics Corp. | Novel substituted bicyclic compounds as bromodomain inhibitors |
| LT3049417T (lt) | 2013-07-31 | 2019-02-11 | Merck Patent Gmbh | Piridinai, pirimidnai ir pirazinai kaip btk inhibitoriai ir jų panaudojimas |
| MA38961A1 (fr) * | 2013-09-30 | 2018-05-31 | Pharmacyclics Llc | Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose |
-
2016
- 2016-01-29 CN CN201610066886.9A patent/CN107021963A/zh not_active Withdrawn
- 2016-12-28 SI SI201631429T patent/SI3409672T1/sl unknown
- 2016-12-28 PL PL16887788T patent/PL3409672T3/pl unknown
- 2016-12-28 ES ES16887788T patent/ES2902128T3/es active Active
- 2016-12-28 SG SG11201806438UA patent/SG11201806438UA/en unknown
- 2016-12-28 DK DK16887788.4T patent/DK3409672T3/da active
- 2016-12-28 CA CA3012882A patent/CA3012882A1/en active Pending
- 2016-12-28 CN CN201680080472.XA patent/CN108602818B/zh active Active
- 2016-12-28 AU AU2016389434A patent/AU2016389434B2/en active Active
- 2016-12-28 LT LTEPPCT/CN2016/112625T patent/LT3409672T/lt unknown
- 2016-12-28 US US16/073,607 patent/US10336755B2/en active Active
- 2016-12-28 PT PT168877884T patent/PT3409672T/pt unknown
- 2016-12-28 JP JP2018539817A patent/JP7043409B2/ja active Active
- 2016-12-28 RS RS20211556A patent/RS62768B1/sr unknown
- 2016-12-28 HR HRP20212020TT patent/HRP20212020T1/hr unknown
- 2016-12-28 WO PCT/CN2016/112625 patent/WO2017128917A1/zh active Application Filing
- 2016-12-28 HU HUE16887788A patent/HUE057319T2/hu unknown
- 2016-12-28 KR KR1020187024923A patent/KR20180104132A/ko not_active Application Discontinuation
- 2016-12-28 EP EP16887788.4A patent/EP3409672B1/en active Active
-
2018
- 2018-12-11 HK HK18115881.0A patent/HK1256798A1/zh unknown
-
2021
- 2021-12-30 CY CY20211101138T patent/CY1124970T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ744870A (en) | 2022-03-25 |
| ES2902128T3 (es) | 2022-03-25 |
| HK1256798A1 (zh) | 2019-10-04 |
| US20190016721A1 (en) | 2019-01-17 |
| DK3409672T3 (da) | 2022-01-10 |
| EP3409672B1 (en) | 2021-12-08 |
| WO2017128917A1 (zh) | 2017-08-03 |
| RS62768B1 (sr) | 2022-01-31 |
| JP2019503393A (ja) | 2019-02-07 |
| KR20180104132A (ko) | 2018-09-19 |
| SI3409672T1 (sl) | 2022-03-31 |
| JP7043409B2 (ja) | 2022-03-29 |
| PL3409672T3 (pl) | 2022-02-21 |
| LT3409672T (lt) | 2022-01-10 |
| CN108602818A (zh) | 2018-09-28 |
| EP3409672A4 (en) | 2019-07-10 |
| CN107021963A (zh) | 2017-08-08 |
| AU2016389434B2 (en) | 2021-03-11 |
| EP3409672A1 (en) | 2018-12-05 |
| WO2017128917A8 (zh) | 2017-09-14 |
| US10336755B2 (en) | 2019-07-02 |
| HUE057319T2 (hu) | 2022-04-28 |
| HRP20212020T1 (hr) | 2022-04-01 |
| AU2016389434A1 (en) | 2018-08-23 |
| CA3012882A1 (en) | 2017-08-03 |
| CN108602818B (zh) | 2021-12-21 |
| PT3409672T (pt) | 2022-01-05 |
| SG11201806438UA (en) | 2018-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1124970T1 (el) | Παραγωγα συγχωνευμενων δακτυλιων πυραζολιου και μεθοδος παρασκευης αυτων και εφαρμογη αυτων σε αντιμετωπιση καρκινων, φλεγμονης και νοσων του ανοσοποιητικου | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| CY1123395T1 (el) | Ενωσεις καρβοξαμιδιων ινδολης χρησιμες ως αναστολεις κινασων | |
| CY1120088T1 (el) | Παραγωγα τυπου αζαϊνδαζολιου ή διαζαϊνδαζολιου ως φαρμακo | |
| CY1122966T1 (el) | 5-βρωμο-2,6-δι-(1η-πυραζολ-1-υλ)πυριμιδιν-4-αμινη για χρηση στη θεραπευτικη αγωγη καρκινου | |
| CY1122566T1 (el) | Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
| CL2020001097A1 (es) | Derivados de piridincarbonilo y usos terapéuticos de los mismos como inhibidores de trpc6. | |
| PH12019500214A1 (en) | Substituted thiazolo-pyridine compounds as malt1 inhibitors | |
| CY1122792T1 (el) | Παραγωγα μονο- ή δισυποκατεστημενης ινδολης ως αναστολεις αναδιπλασιασμου δαγκειου ιου | |
| EA201892216A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201892219A1 (ru) | Замещенные производные индолина в качестве ингибиторов репликации вирусов денге | |
| EA201892214A1 (ru) | Замещенные производные индола в качестве ингибиторов репликации вирусов денге | |
| PH12019501896A1 (en) | Therapeutic dendrimers | |
| EA201791535A1 (ru) | Новое соединение 4'-тионуклеозида, а также способ его получения, его фармацевтическая композиция и применение | |
| CY1121930T1 (el) | Θεραπευτικοι παραγοντες για νευροεκφυλιστικες ασθενειες | |
| CY1117881T1 (el) | Στερεες φαρμακευτικες συνθεσεις που περιλαμβανουν παραγωγα βιοπτερινης και χρησεις αυτων των συνθεσεων | |
| EA202191478A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| EA202190588A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина | |
| CY1121921T1 (el) | Φαρμακευτικα σκευασματα | |
| EA202191477A1 (ru) | Гетероароматические соединения в качестве ингибиторов ванина |